In focus · trending topic

PNH

41 stories · following the connections

Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs

By Nasdaq OMXMay 4, 2017, 10:05 AM UTC

Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference

By Nasdaq OMXMay 2, 2017, 10:05 AM UTC

Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets

By Nasdaq OMXApr 24, 2017, 11:15 AM UTC

Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria

By Nasdaq OMXApr 6, 2017, 10:05 AM UTC

Akari Therapeutics to Present at the Jefferies Complement Symposium

By Nasdaq OMXApr 3, 2017, 11:01 AM UTC

Akari Therapeutics to Present at the Jefferies Complement Symposium

By Nasdaq OMXApr 3, 2017, 11:01 AM UTC

Akari Therapeutics Announces FDA Fast Track Designation For Coversin

By Nasdaq OMXMar 30, 2017, 8:02 PM UTC

Akari Therapeutics Announces R&D Day on April 24, 2017

By Nasdaq OMXMar 17, 2017, 11:00 AM UTC